Read more

June 02, 2022
1 min read
Save

Top in hem/onc: Microaggressions in the workplace; height-related cancer risk

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

An education session at the ASCO Annual Meeting will review strategies to address bias and microaggressions in the medical workplace.

In an exclusive video with Healio, Narjust Duma, MD, a thoracic oncologist at Dana-Farber Cancer Institute and associate director of the Cancer Care Equity Program, previewed the session, “Microaggressions, Bias and Equity in the Workplace.” It was the top story in hematology/oncology last week.

Three Doctors - One Young, One Older, One Black, Collaborating
Source: Adobe Stock

The second top story was about research demonstrating an increased risk for colorectal cancer and adenoma among taller adults. In light of the findings, researchers recommended that height be considered a risk factor for colorectal cancer screening.

Read these and more top stories in hematology/oncology below:

VIDEO: How to deal with bias, microaggressions in the medical workplace

In this video, Duma previews an ASCO Annual Meeting education session that will define microaggressions and describe strategies and actions that can be taken to improve the workplace environment. Read more.

Taller adults may have higher risk for colorectal cancer, adenoma

Greater adult-attained height correlated with increased risk for colorectal cancer and adenoma, according to a meta-analysis published in Cancer, Epidemiology, Biomarkers & Prevention. Read more.

With a little ‘love,’ health system culture can be changed for the better

Several years ago, our health care system developed core values and behaviors from the grassroots level up. This was the brainchild of our president and CEO, Janice E. Nevin, MD, MPH, who is a family medicine physician. Read more.

CAR-T shows ‘remarkable’ efficacy as first-line therapy for large B-cell lymphoma

First-line therapy with axicabtagene ciloleucel induced objective responses in 89% of patients with high-risk large B-cell lymphoma, according to phase 2 study results. Read more.

World Trade Center responders have higher burden of mutations linked to blood cancers

First responders to the World Trade Center had higher rates of clonal hematopoiesis-associated mutations than firefighters not exposed to the dust, gases and potential carcinogens at the site, according to a study in Nature Medicine. Read more.